跳至主要内容
临床试验/NCT04667572
NCT04667572已完成1 期

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Conditions

Cornea Associates of Texas2 个研究点 分布在 1 个国家目标入组 249 人开始时间: 2021年2月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
249
试验地点
2
主要终点
K-Max

研究概览

简要总结

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions

详细描述

Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal topography, visual acuity, pachymetry, and visual function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
8 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 8 years of age or older
  • Signed written informed consent
  • Willingness and ability to comply with schedule for follow-up visits
  • Contact Lens Wearers Only:
  • Removal of contact lenses (if applicable) for the required period of time prior to the screening refraction: Soft, discontinue 3 days; Soft Extended Wear, discontinue 3 days; Soft Toric, discontinue 3 days; Rigid gas permeable, discontinue 2 Weeks (subjects who cannot function without wearing their contact lenses, may forgo discontinuation of contact lenses)
  • And one or more of the following:
  • Presence of central or inferior steepening.
  • Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration
  • Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as: Fleischer ring, Vogt's striae, Decentered corneal apex, Munson's sign, Rizzutti's sign, Apical Corneal scarring consistent with Bowman's breaks, Scissoring of the retinoscopic reflex, Crab-claw appearance on topography
  • Steepest keratometry (Kmax) value ≥ 47.20 D
  • I-S keratometry difference > 1.5 D on the Pentacam/Orbscan map or topography map
  • Posterior corneal elevation >16 microns
  • Thinnest corneal point >300 microns

排除标准

  • Eyes classified as either normal or atypical normal on the severity grading scheme.
  • Corneal thickness < 300 microns measured by ultrasonic pachymetry or pentacam.
  • Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example: History of or active corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, etc.) Clinically significant corneal scarring in the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross-linking procedure.
  • Pregnancy (including plan to become pregnant) or lactation during the course of the study
  • A known sensitivity to study medications
  • Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests.
  • Patients with a current condition that, in the physician's opinion, would interfere with or prolong epithelial healing

结局指标

主要结局

K-Max

时间窗: 12 Months

Change in K-Max measured by corneal topography, compared to baseline

K-Mean

时间窗: 12 Months

Change in K-Mean measured by corneal topography, compared to baseline

次要结局

  • Uncorrected Visual Acuity(12 Months)
  • Best Corrected Visual Acuity(12 Months)
  • Central Pachymetry(12 Months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验